Undisclosed anti-PD-1×CTLA-4×VEGF TsAb
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
A novel anti-PD-1×CTLA-4×VEGF tri-specific antibody enables tumor-selective immune checkpoint blockade with potent anti-tumor activity
(AACR 2026)
- "Abstract is embargoed at this time."
Checkpoint block • Checkpoint inhibition • Late-breaking abstract • Trispecific • Oncology
1 to 1
Of
1
Go to page
1